Gonorrhea Therapeutics Market by Therapy and Geography - Forecast and Analysis 2020-2024

  • Published: Aug 2020
  • Pages: 120
  • SKU: IRTNTR44632
Technavio

The 2021-2025 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

The gonorrhea therapeutics market size has the potential to grow by USD 350.90 million during 2020-2024, and the market’s growth momentum will accelerate during the forecast period.

This report provides a detailed analysis of the market by therapy (monotherapy and combination therapy) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including AstraZeneca Plc, Bristol-Myers Squibb Co., Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lupin Ltd., Merck & Co. Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Market Overview

Browse TOC and LoE with selected illustrations and example pages of Gonorrhea Therapeutics Market

Request a FREE sample now!

Market Competitive Analysis

The gonorrhea therapeutics market is fragmented with the presence of both global and regional vendors. Vendors are partnering with research organizations and hospitals for R&D and are participating in various scientific conferences to showcase their products. Such efforts will provide long-term development opportunities to them. The key vendors in the global gonorrhea therapeutics market are focusing on product approvals and M&A to gain a competitive edge in the market. Inorganic growth strategies, robust R&D, and pricing strategies will increase competition among these vendors. AstraZeneca Plc, Bristol-Myers Squibb Co., and Cipla Inc. are some of the major market participants. Although the growing use of new diagnostic tests will offer immense growth opportunities, the emergence of antibiotic-resistant gonococcal strain will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

To help clients improve their market position, this gonorrhea therapeutics market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market’s competitive landscape and offers information on the products offered by various companies. Moreover, this gonorrhea therapeutics market analysis report also provides information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.

This report provides information on the production, sustainability, and prospects of several leading companies, including:

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Lupin Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Gonorrhea Therapeutics Market: Segmentation by Geography

For more insights on the market share of various regions Request for a FREE sample now!

North America was the largest gonorrhea therapeutics market in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. 50% of the market’s growth will originate from North America during the forecast period. The US is a key market for gonorrhea therapeutics in North America. However, the market growth in this region will be slower than the growth of the market in Asia.

Gonorrhea Therapeutics Market: Segmentation by Therapy

Request for a FREE sample and Get more information on the market contribution of various segments

Monotherapy involves the application of one single drug at a time for the treatment of gonorrhea disease. The therapy either uses oral cefixime or IM ceftriaxone. The monotherapy segment is more popular than dual therapy due to the high efficacy of these drugs, the ease of administration of oral cefixime, and their cost-effectiveness. The adoption of monotherapy will continue to grow in the gonorrhea treatment market during the next five years due to the high potency of ceftriaxone IM or IV. This report provides an accurate prediction of the contribution of all the segments to the growth of the gonorrhea therapeutics market size.

Gonorrhea Therapeutics Market: Key Drivers and Trends

Technavio’s research analysis on the global gonorrhea therapeutics market has identified that the growing use of new diagnostic tests will be one of the major factors that will have a positive impact on the market growth in the coming years. The rising incidence of gonorrhea has resulted in the emergence of new diagnostic tests such as nucleic acid amplification tests (NAATs). This allows an early diagnostic screening to avoid the spread of the infection to the upper genital tract. People suffering from gonorrhea are advised to take the appropriate antibiotics for gonorrhea and repeat the gonorrhea test after three to six months. Traditional culture, nucleic acid hybridization, and NAATs are a few of the diagnostic tests that confirm the presence of Neisseria gonorrhoeae. NAATs are highly preferred over traditional cultures since they show improved sensitivity and selectivity for Neisseria gonorrhoeae at rectal and oropharyngeal sites in men. The availability of highly sensitive and selective testing modalities drives the demand for gonorrhea therapeutics, in turn, propelling market growth. Our market research analysts predict that this global market will grow at a CAGR of almost 5% during the forecast period

One of the key trends that will gain traction in the gonorrhea therapeutics market during the estimated period is the rise in government initiatives to combat antibiotic resistance. According to the Centers for Disease Control and Prevention (CDC), the US government released a plan to ‘Combat Antibiotic-Resistant Bacteria’ (CARB). This helps in the prevention, detection, and control of antibiotic resistance. Consequently, this control of antibiotic resistance in gonorrheal infection will increase patient adherence towards antibiotic therapy.

Event-Tickets-Market-Report

Request for a FREE sample

Gonorrhea Therapeutics Market: Key Highlights of the Report for 2020-2024

  • CAGR of the market during the forecast period 2020-2024
  • Detailed information on factors that will drive gonorrhea therapeutics market growth during the next five years
  • Precise estimation of the gonorrhea therapeutics market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the gonorrhea therapeutics industry across Asia, Europe, North America, and ROW
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of gonorrhea therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Read More Read Less

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
The gonorrhea therapeutics market growth will increase by $350.90 million during 2019-2024.
The gonorrhea therapeutics market is expected to grow at a CAGR of 4.63% during 2019-2024.
Technavio has segmented the gonorrhea therapeutics market by other1 (Monotherapy and Combination therapy) and geographic (North America, Europe, Asia, and ROW).
AstraZeneca Plc, Bristol-Myers Squibb Co., Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lupin Ltd., Merck & Co. Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. are a few of the key vendors in the gonorrhea therapeutics market.
North America will register the highest growth rate of 49.67% among the other regions. Therefore, the gonorrhea therapeutics market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
The key factors driving the gonorrhea therapeutics market growth are:
  • Rising prevalence of disease
  • Rising government initiatives to combat antibiotic resistance
The gonorrhea therapeutics market vendors should focus on grabbing business opportunities from the monotherapy segment as it accounted for the largest market share in the base year.
Safe and Secure SSL Encrypted
Technavio

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase

Technavio's SUBSCRIPTION platform

Register for a free trial today and gain instant access to 17,000+ market research reports.

START YOUR FREE TRIAL

Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>